Insulin degludec as an ultralong-acting basal insulin once a day: a systematic review

Fei Wang,1 Justine Surh,1 Manmeet Kaur21University of Connecticut School of Pharmacy, Department of Pharmacy Practice, Storrs, 2Joslin Diabetes Center Affiliate, Hospital of Central Connecticut, New Britain, CT, USABackground: Insulin degludec (IDeg) is a neutral, ultralong-acting new generation bas...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Wang F, Surh J, Kaur M
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2012
Materias:	Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/0edc798221ed4ca4b84db80b9a1d4bb9
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:0edc798221ed4ca4b84db80b9a1d4bb9
record_format	dspace
spelling	oai:doaj.org-article:0edc798221ed4ca4b84db80b9a1d4bb92021-12-02T01:39:20ZInsulin degludec as an ultralong-acting basal insulin once a day: a systematic review1178-7007https://doaj.org/article/0edc798221ed4ca4b84db80b9a1d4bb92012-07-01T00:00:00Zhttp://www.dovepress.com/insulin-degudec-as-an-ultralong-acting-basal-insulin-once-a-day-a-sys-a10312https://doaj.org/toc/1178-7007Fei Wang,1 Justine Surh,1 Manmeet Kaur21University of Connecticut School of Pharmacy, Department of Pharmacy Practice, Storrs, 2Joslin Diabetes Center Affiliate, Hospital of Central Connecticut, New Britain, CT, USABackground: Insulin degludec (IDeg) is a neutral, ultralong-acting new generation basal insulin analog developed by NovoNordisk currently in Phase III clinical development. IDeg offers a duration of action of more than 42 hours in adults, much longer than current basal insulin formulations.Objective: The aim of this review is to assess the efficacy and safety data of IDeg in the treatment of type 1 and type 2 diabetes mellitus.Methods: Relevant English language articles from 2010 to 2012 were identified through MEDLINE, PubMed, EMBASE, Scopus, BIOSIS, and Google Scholar. Online conference proceedings of the 71st ADA Scientific Sessions and the 47th EASD Annual Meeting were reviewed. Studies were compared in terms of their study designs, primary and secondary efficacy parameters, and tolerability data.Results: There are a total of nine published trials investigating the clinical efficacy and safety of IDeg in over 3000 subjects with type 1 and 2 diabetes. Only three trials were published in full. All were open-label, randomized multicenter trials with durations of 16 to 52 weeks. IDeg and coformulations of IDeg with insulin aspart (IAsp) were compared to insulin glargine (IGlar), detemir, and biphasic IAsp 30 (BIAsp 30).Conclusion: Based upon the available evidence, there appear to be no reported differences between IDeg and IGlar, detemir, or BIAsp 30 in the reduction of the primary efficacy end-points of HbA1c and mean fasting plasma glucose (FPG) concentrations. Only flexible dosing of IDeg provided a significant reduction in FPG compared to IGlar. IDeg demonstrated a significant reduction in nocturnal hypoglycemia in type 1 diabetes. In type 2 diabetes, IDeg reduced the incidence of hypoglycemia by 18% and 58% compared to IGlar and BIAsp 30, respectively.Keywords: basal insulin analog/analogue, degludec, degludec/aspart, IDeg, IDegAsp, NN1250, efficacy, safety, comparative studyWang FSurh JKaur MDove Medical PressarticleSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol 2012, Iss default, Pp 191-204 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Specialties of internal medicine RC581-951
spellingShingle	Specialties of internal medicine RC581-951 Wang F Surh J Kaur M Insulin degludec as an ultralong-acting basal insulin once a day: a systematic review
description	Fei Wang,1 Justine Surh,1 Manmeet Kaur21University of Connecticut School of Pharmacy, Department of Pharmacy Practice, Storrs, 2Joslin Diabetes Center Affiliate, Hospital of Central Connecticut, New Britain, CT, USABackground: Insulin degludec (IDeg) is a neutral, ultralong-acting new generation basal insulin analog developed by NovoNordisk currently in Phase III clinical development. IDeg offers a duration of action of more than 42 hours in adults, much longer than current basal insulin formulations.Objective: The aim of this review is to assess the efficacy and safety data of IDeg in the treatment of type 1 and type 2 diabetes mellitus.Methods: Relevant English language articles from 2010 to 2012 were identified through MEDLINE, PubMed, EMBASE, Scopus, BIOSIS, and Google Scholar. Online conference proceedings of the 71st ADA Scientific Sessions and the 47th EASD Annual Meeting were reviewed. Studies were compared in terms of their study designs, primary and secondary efficacy parameters, and tolerability data.Results: There are a total of nine published trials investigating the clinical efficacy and safety of IDeg in over 3000 subjects with type 1 and 2 diabetes. Only three trials were published in full. All were open-label, randomized multicenter trials with durations of 16 to 52 weeks. IDeg and coformulations of IDeg with insulin aspart (IAsp) were compared to insulin glargine (IGlar), detemir, and biphasic IAsp 30 (BIAsp 30).Conclusion: Based upon the available evidence, there appear to be no reported differences between IDeg and IGlar, detemir, or BIAsp 30 in the reduction of the primary efficacy end-points of HbA1c and mean fasting plasma glucose (FPG) concentrations. Only flexible dosing of IDeg provided a significant reduction in FPG compared to IGlar. IDeg demonstrated a significant reduction in nocturnal hypoglycemia in type 1 diabetes. In type 2 diabetes, IDeg reduced the incidence of hypoglycemia by 18% and 58% compared to IGlar and BIAsp 30, respectively.Keywords: basal insulin analog/analogue, degludec, degludec/aspart, IDeg, IDegAsp, NN1250, efficacy, safety, comparative study
format	article
author	Wang F Surh J Kaur M
author_facet	Wang F Surh J Kaur M
author_sort	Wang F
title	Insulin degludec as an ultralong-acting basal insulin once a day: a systematic review
title_short	Insulin degludec as an ultralong-acting basal insulin once a day: a systematic review
title_full	Insulin degludec as an ultralong-acting basal insulin once a day: a systematic review
title_fullStr	Insulin degludec as an ultralong-acting basal insulin once a day: a systematic review
title_full_unstemmed	Insulin degludec as an ultralong-acting basal insulin once a day: a systematic review
title_sort	insulin degludec as an ultralong-acting basal insulin once a day: a systematic review
publisher	Dove Medical Press
publishDate	2012
url	https://doaj.org/article/0edc798221ed4ca4b84db80b9a1d4bb9
work_keys_str_mv	AT wangf insulindegludecasanultralongactingbasalinsulinonceadayasystematicreview AT surhj insulindegludecasanultralongactingbasalinsulinonceadayasystematicreview AT kaurm insulindegludecasanultralongactingbasalinsulinonceadayasystematicreview
_version_	1718402941395664896

Insulin degludec as an ultralong-acting basal insulin once a day: a systematic review

Ejemplares similares